

EXPRESS MAIL CERTIFICATE

Date 4/13/91 Label No. 853599132Us

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

Name (Print)

Signature

PLEASE CHARGE ANY DEFICIENCY
UP TO \$300.00 OR CREDIT ANY
EXCESS IN THE FEES DUE WITH
THIS DOCUMENT TO OUR DEPOSIT
ACCOUNT NO. 04-0100

Docket No.:3380/11127-US4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Papsidero *et al.*

Serial No: TBA

Examiner: TBA

Filed: Concurrently Herewith

Group Art Unit: TBA

For: DETECTION AND TREATMENT OF BREAST DISEASE

PRELIMINARY REMARKS

Hon. Commissioner of Patents
Washington, DC 20231

Sir:

Prior to examination of the application submitted herewith, consideration of the following remarks is requested. The present application is a divisional application of pending U.S. Patent Application Serial No.: 09/146,580 filed on September 3, 1998. The present application contains amendments to the specification.

(1) The application has been amended to reflect the continuing data.

(2) The sequence identification numbers have been revised to follow the sequence listing submitted herewith.

(3) The description of Figure 1 (page 5, lines 17-26) has been amended to incorporate new SEQ ID NOs: 20-34 present in the figure. Support for these sequences is in original Figure 1.


(4) SEQ ID NO: 7 (see page 20, lines 20-27) has been amended to correctly identify the coding sequence of the protein depicted in SEQ ID NO:1. The encoded protein (SEQ ID NO:1) contains a methionine residue in position 1. In order for SEQ ID NO:7 to encode a methionine residue at position 1, the first codon should be ATG, not TGC (which is the codon for cysteine). Clearly, a typographical error resulted in omission of the 5'-most "A" base. Support for this nucleic acid sequence is found on page 18, line 8 to page 20, line 4 of the parent application (specifically, see residues 46-430) and the deduced amino acid sequence (page 6, lines 21-23).

(5) Reference to Table 1, ID#189 on page 44, lines 2-4 in the original specification has been amended to refer to Table 3, ID#189 (see page 45, lines 1-5). ID#189 is described in Table 3, not Table 1, of the original specification.

No new matter has been added by these amendments.

Dated: April 13, 2001

Respectfully submitted,


Neepa Y. Choksi
Registration No. 47,488
Agent for Applicant(s)